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Abstract
Background: Antimicrobial peptides (AMPs) are receiving increasing attention due to resistance development against
conventional antibiotics. Pseudomonas aeruginosa and Staphylococcus aureus are two major pathogens involved in an array
of infections such as ocular infections, cystic fibrosis, wound and post-surgery infections, and sepsis. The goal of the study
was to design novel AMPs against these pathogens.
Methodology and Principal Findings: Antibacterial activity was determined by radial diffusion, viable count, and minimal
inhibitory concentration assays, while toxicity was evaluated by hemolysis and effects on human epithelial cells. Liposome
and fluorescence studies provided mechanistic information. Protease sensitivity was evaluated after subjection to human
leukocyte elastase, staphylococcal aureolysin and V8 proteinase, as well as P. aeruginosa elastase. Highly active peptides
were evaluated in ex vivo skin infection models. C-terminal end-tagging by W and F amino acid residues increased
antimicrobial potency of the peptide sequences GRRPRPRPRP and RRPRPRPRP, derived from proline arginine-rich and
leucine-rich repeat protein (PRELP). The optimized peptides were antimicrobial against a range of Gram-positive S. aureus
and Gram-negative P. aeruginosa clinical isolates, also in the presence of human plasma and blood. Simultaneously, they
showed low toxicity against mammalian cells. Particularly W-tagged peptides displayed stability against P. aeruginosa
elastase, and S. aureus V8 proteinase and aureolysin, and the peptide RRPRPRPRPWWWW-NH2 was effective against various
‘‘superbugs’’ including vancomycin-resistant enterococci, multi-drug resistant P. aeruginosa, and methicillin-resistant S.
aureus, as well as demonstrated efficiency in an ex vivo skin wound model of S. aureus and P. aeruginosa infection.
Conclusions/Significance: Hydrophobic C-terminal end-tagging of the cationic sequence RRPRPRPRP generates highly
selective AMPs with potent activity against multiresistant bacteria and efficiency in ex vivo wound infection models. A
precise ‘‘tuning’’ of toxicity and proteolytic stability may be achieved by changing tag-length and adding W- or F-amino acid
tags.
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Introduction
In order to control microbial flora, humans are armoured with a
rapidly acting antimicrobial system based on short cationic and
amphiphilic antimicrobial peptides (AMP), which constitute an
integral part of innate immunity. At present, there are approxi-
mately 1600 identified AMPs (see http://aps.unmc.edu/AP/
main.php). Linear AMPs, such as the cathelicidin LL-37, but
also magainin-2, PGLa, and pleurocidin, adopt highly ordered
amphipathic helices in phospholipid environments and upon
bacterial binding [1,2,3,4,5,6,7]. Other peptides, such as a- and b-
defensins, comprise amphipathic cysteine-linked antiparallel b-
sheets [8,9]. AMPs may also, however, be found among peptides
not displaying such ordered structures as long as these are
characterized by an over-representation of certain amino acids,
such as histidine (e.g., histatins), or arginine (e.g., PR39)
[1,2,3,4,10]. AMP function has been thought to involve direct
binding to the lipid bilayer, and the interaction with bacterial
membranes is a prerequisite for AMP function. However, the
modes of action of AMPs on their target bacteria are complex, and
can be divided into membrane disruptive and non-membrane
disruptive [3,11,12,13].
It has become increasingly clear that AMPs belong to a
multifunctional group of molecules that interact not only with
microbes, but also with negatively charged glycosaminoglycans
(such as heparin), biomembranes, and various cell receptors.
Apart from their antibacterial actions, biological effects exerted
by AMPs include growth stimulus and angiogenesis, protease
inhibition, anti-angiogenesis, and chemotaxis [14,15,16]. Con-
versely, cationic peptide motifs from proteins not previously
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activities. For example, complement C3 [17], kininogen [18,19],
heparin-binding protein [20], heparin-binding epidermal growth
factor and other growth factors [21], matrix proteins such as
laminin, fibronectin and proline arginine-rich end leucine-rich
repeat protein (PRELP)[22], prions [23], b2-glycoprotein [24],
histidine-rich glycoprotein [25], thrombin [26], and tissue factor
pathway inhibitor [27], may, either as holoproteins or smaller
peptide derivatives or fragments thereof, also exert antimicrobial
activities inv i t r o , and in several cases, in vivo [18,19,25]. In
general, these findings are compatible with the observation that
consensus heparin-binding peptide sequences (Cardin and
Weintraub motifs) XBBBXXBX or XBBXBX (where X
represents hydrophobic or uncharged amino acids, and B
represents basic amino acids), represented by multiples of the
motifs ARKKAAKA or AKKARA [28], are antibacterial [29]
and specifically interact with membranes [30].
Infectious diseases account for millions of deaths worldwide
each year and incur tremendous health care costs. The disease
spectrum is broad and includes acute disease, such as acute local
or invasive infections, including sepsis, having a direct associa-
tion to a given pathogen, as well as chronic diseases, where
microbes often cause a long-standing inflammatory state.
Pathogens such as Staphylococcus aureus and Pseudomonas aeruginosa
cause, and/or aggravate, a spectrum of diseases including
bacterial conjunctivitis and keratitis, otitis, postoperative and
burn wound infections, chronic leg ulcers, pneumonia, and cystic
fibrosis. Community-acquired MRSA has now emerged as an
epidemic that is responsible for rapidly progressive, fatal diseases
including necrotizing pneumonia, severe sepsis, and necrotizing
fasciitis [31]. Concerning streptococci, strains of S. pyogenes
resistant to macrolide antibiotics have emerged, however all
strains still remain uniformly sensitive to penicillin. In addition,
enterococci, leading causes of nosocomial bacteremia, surgical
wound infection, and urinary tract infection, are becoming
intrinsically resistant to many antibiotics [32]. P. aeruginosa is
emerging, particularly in critically ill patients that require
intensive care and are treated with multiple antibiotic agents
(see http://www.cdc.gov for further information). Therefore,
multi-drug resistant P. aeruginosa infections are associated with
severe adverse clinical outcomes [33]. As mentioned above, all
these bacteria may complicate wounds. In addition, wound
infection is one of the most common surgical complications,
leading to significant mortality and morbidity. Surgical site
infections are the most common form of hospital-acquired
infections for surgical patients and occur in between 10-38%
(UK and US respectively) of patients. These infections, which
occur in 15% of elective surgical patients and approximately
30% of surgical patients whose procedure was classed as
contaminated or ‘‘dirty’’, delay wound healing, prolong hospital
stay, cause unnecessary pain and also, increase the risk for
invasive infections and sepsis [34].
Considering the increasing resistance problems against con-
ventional antibiotics, AMPs have recently emerged as potential
therapeutic candidates in the above conditions [35]. For
example, the indolicidin-derived peptide omiganan is currently
being evaluated in Phase III clinical trials for treatment of
catheter-related infections [36]. However, the use of AMPs in this
context is challenging, as bacteria are able to excrete proteolytic
enzymes [37,38], and in the case of P. aeruginosa also AMP-
scavenging exopolysaccharides, as a defense against AMPs.
Furthermore, S. aureus displays an impressive number of
resistance mechanisms, including net charge alterations [39,40].
Thus, the teichoic acid polymers found in the cell wall of this
bacterium, as well as in those of other Gram-positives, normally
having strong anionic properties mediated by phosphate groups
of the glycerolphosphate repeating units, can be modified by D-
alanine residues with free amino groups. Analogously, the major
(and negatively charged) lipid phosphatidylglycerol is modified
into a net positive charge by addition of L-lysine [3,41]. Ideally,
therefore, AMPs should display high bactericidal potency and
protease stability, but low toxicity against mammalian cells.
Various strategies, such as use of combinational library
approaches [42], stereoisomers composed of D-amino acids
[43] or cyclic D,L-a-peptides [44], high-throughput based
screening assays [45,46], quantitative structure-activity relation-
ship (QSAR) approaches [35,45,47,48], and identification of
endogenous peptides [22,26,49,50,51,52], are currently em-
ployed for identifying selective and therapeutically interesting
AMPs [53,54]. Utilization of endogenous antimicrobial peptide
sequences could constitute an attractive alternative strategy in
order to develop novel antiinfectives, and as mentioned above, a
PRELP-derived peptide, QPTRRPRPGTGPGRRPRPRPRP,
was previously found to exert antimicrobial effects against both
P. aeruginosa and S. aureus [22]. Analysis by fluorescence
microscopy demonstrated that QPT22 bound to bacterial
membranes and induced membrane leakage of liposomes.
Furthermore, the peptide displayed no hemolytic activity, nor
did it exert membrane permeabilising effects on human epithelial
cells. In a parallel line of research, we previously identified end-
tagging of AMPs with hydrophobic amino acid stretches as an
effective approach to achieve high adsorption of partially
submerged, highly charged AMPs [55,56,57]. Given this, and
the abovementioned ability of S. aureus to reduce its surface
charge density, hydrophobic end-tagging of AMPs with hydro-
phobic amino acid stretches is an interesting way to improve
bactericidal potency of AMPs. Particularly for short, highly
positively charged, and hydrophilic peptides, this facilitates the
design of potent, but selective, AMPs. Previous physico-chemical
investigations, involving studies on peptide adsorption at
supported lipid bilayers, peptide-induced liposome rupture, as
well as LPS-binding experiments, circular dichroism experiments
on peptide conformation, and studies on bacterial wall rupture,
demonstrated that the end-tagged peptides reach their potency
and salt resistance through the hydrophobic end-tags, promoting
peptide adsorption at phospholipid membranes. The selectivity
between bacteria and eukaryotic cells could also be explained on
a mechanistic level, and due to the lower charge density of
eukaryotic cell membrane, combined with the presence of
cholesterol in the latter [55,56,57]. Based on these results, and
considering the promising results with the PRELP-derived AMP
mentioned above [22], we selected the peptides GRRPRPRPRP
(GRR10) and RRPRPRPRP (RRP9) (derived from the C-
terminal part of QPTRRPRPGTGPGRRPRPRPRP) as tem-
plates for C-terminal tagging hydrophobic amino acid stretches
in order to generate novel effective AMPs.
Herein the present report, we demonstrate that tagging these
PRELP-derived AMPs with W and F amino acid residues may be
employed to reach very high bactericidal potency against various
important Gram-negative and Gram-positive pathogens at
maintained limited toxicity. Furthermore, toxicity as well as
proteolytic stability may be selectively tuned. In addition, by
varying tag length and composition, we demonstrate that
incorporation of W-stretches, in contrast to F, yields good stability
against human elastase, as well as S. aureus and P. aeruginosa
proteases. This is an important aspect for the therapeutic use of
AMPs in environments containing high proteolytic activity, such
as those occurring during inflammation and infection.
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Ethics statement
The use of human blood was approved by the Ethics
Committee at Lund University (657-2008). Written informed
consent was obtained from the donors.
Peptides
Peptides used in this work (Table 1) were synthesized by
Biopeptide Co., San Diego, USA, with the exception of LL-37
(LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES),
which was obtained from Innovagen AB, Lund, Sweden. The
purity (.95%) of these peptides was confirmed by mass spectral
analysis (MALDI-ToF Voyager), provided by the suppliers.
Peptides were diluted in H20 (5 mM stock), and stored at
–20uC, until used. This stock solution was used for the subsequent
experiments.
Microorganisms
Escherichia coli ATCC 25922, Staphylococcus aureus ATCC 29213,
and Pseudomonas aeruginosa ATCC 27853, as well as the other
clinical isolates, were obtained from the Department of Clinical
Bacteriology at Lund University Hospital. Additional isolates
presented in Table 2 were maintained and tested at Quotient
Bioresearch, Cardiff, United Kingdom.
Radial diffusion assay
Radial diffusion assay was used in order to evaluate antibac-
terial effects. As previously described [58,59], bacteria were grown
to mid-logarithmic phase in 10 ml of full-strength (3% w/v)
trypticase soy broth (TSB) (Becton-Dickinson, Cockeysville, USA).
The cells were then washed once with 10 mM Tris, pH 7.4.
Subsequently, 4610
6 bacterial colony forming units were added to
15 ml of the underlay agarose gel, consisting of 0.03% (w/v) TSB,
1% (w/v) low electroendosmosis type (EEO) agarose (Sigma-
Aldrich, St. Louis, USA) and 0.02% (v/v) Tween 20 (Sigma-
Aldrich, St. Louis, USA). The underlay was poured into a Ø
144 mm petri dish. After agarose solidification, 4 mm-diameter
wells were punched and 6 ml of peptide with required concentra-
tion was added to each well. Plates were incubated at 37uC for
3 hours to allow diffusion of the peptides. The underlay gel was
then covered with 15 ml of molten overlay (6% TSB and 1% Low-
EEO agarose in distilled H2O). Antimicrobial activity of a peptide
is visualized as a zone of clearing around each well after 18–
24 hours of incubation at 37uC. Results given represent mean
values from triplicate measurements.
Viable-count analysis
For additional evaluation of bactericidal effects, Staphylococcus
aureus ATCC 29213 and Pseudomonas aeruginosa ATCC 27853
bacteria (50 ml; 2610
6 cfu/ml) were grown to mid-logarithmic
phase in Todd-Hewitt (TH) medium. Bacteria were washed and
diluted in 10 mM Tris, pH 7.4, 5 mM glucose, 0.15 M NaCl, with
20% human citrate-plasma. After peptide exposure, serial
dilutions of the incubation mixture were plated on TH agar,
followed by incubation at 37uC overnight and cfu determination.
In the experiments using 50% whole blood [26], S. aureus ATCC
29213 and P. aeruginosa ATCC 27853 bacteria (50 ml; 2610
8 cfu/
ml) were incubated at 37uC for 1 hour in the presence of peptide
at 60 and 120 mM. Serial dilutions of the incubation mixture were
plated on TH agar, followed by incubation at 37uC overnight and
cfu determination.
Minimal inhibitory concentration (MIC) determination
In order to determine the minimal inhibitory concentration
(MIC) for a given peptide and bacteria, we used a standardized
dilution method according to NCSLA guidelines [60]. In brief,
fresh overnight colonies were suspended to a turbidity of 0.5 units
and further diluted in Mueller-Hinton broth (MH) (Becton
Dickinson). For determination of MIC, peptides were dissolved
in water at concentration 10 times higher than the required range
by serial dilutions from a stock solution. Ten ml of each
concentration was added to each corresponding well of a 96-well
microtiter plate (polypropylene, Costar Corp.) and 90 mlo f
bacteria (1610
5) in MH medium added. The plate was incubated
at 37uC for 16–18 h. MIC was considered as the lowest
concentration of peptide where no visual growth of bacteria was
detected. Additional MIC determinations presented in Table 2
were performed using cation-adjusted MH broth [60] at Quotient
Bioresearch Ltd., Fordham, United Kingdom.
Protease sensitivity assay
For evaluation of sensitivity to bacterial and endogenous
proteases, peptides (1 mg) were incubated at 37uC with S. aureus
aureolysin (0.1 mg, 25000 units/mg), S. aureus V8 proteinase (0.1 mg,
2000 mU), both from BioCol GmbH (Potsdam, Germany), human
neutrophil elastase (0.4 mg, 29 units/mg; Calbiochem (La Jolla,
USA)) or P. aeruginosa elastase (0.1 mg, 261 units/mg) (Calbiochem,
La Jolla, USA) in a total volume of 30 ml for 3 hours. The materials
Table 1. Characteristics of peptides used in the study.
Sequence
Hydrophobicity
Kyte & Dolittle
Hydrophobicity
CCS scale net charge
GRRPRPRPRP-COOH 22.93 25.32 +5
GRRPRPRPRPWWW-
COOH
22.46 21.85 +5
GRRPRPRPRPWWWW-
COOH
22.35 21.02 +5
GRRPRPRPRPWWWWW-
COOH
22.25 20.31 +5
GRRPRPRPRP-NH2 22.93 25.32 +6
GRRPRPRPRPWWW-NH2 22.46 21.85 +6
GRRPRPRPRPWWWW-
NH2
22.35 21.02 +6
GRRPRPRPRPFFF-COOH 21.6 21.78 +5
GRRPRPRPRPFFFF-
COOH
21.29 20.94 +5
GRRPRPRPRPFFFFF-
COOH
21.02 20.21 +5
GRRPRPRPRPFFF-NH2 21.6 21.78 +6
GRRPRPRPRPFFFF-NH2 21.29 20.94 +6
GRRPRPRPRPFFFFF-NH2 21.02 20.21 +6
RRPRPRPRPWWW-NH2 22.63 21.8 +6
RRPRPRPRPWWWW-NH2 22.5 20.92 +6
RRPRPRPRPFFFFF-COOH 21.06 20.05 +5
RRPRPRPRPFFF-NH2 21.7 21.73 +6
RRPRPRPRPFFFF-NH2 21.36 20.83 +6
RRPRPRPRPFFFFF-NH2 21.06 20.05 +6
ILRWPWWPWRRK-NH2 21.32 1.4 +5
LLGDFFRKSKEKIGK
EFKRIVQRIKDFLRN
LVPRTES-COOH
20.72 21.84 +6
doi:10.1371/journal.pone.0016400.t001
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amide (SDS-PAGE) Tris-Tricine gels (BioRad, Hercules, USA) and
analyzed after staining with Coomassie Blue R-250 (Merck,
Darmstadt, Germany).
MTT assay
The MTT assay was utilized in order to analyse cell viability of
keratinocytes. Sterile filtered MTT (3-(4,5-dimethylthiazolyl)-2,5-
diphenyl-tetrazolium bromide; Sigma-Aldrich, St. Louis, USA)
solution (5 mg/ml in PBS) was stored protected from light at
220uC until usage. HaCaT keratinocytes (kindly provided by Dr.
Robert Fusenig, Heidelberg University, Heidelberg, Germany,
[51]), 3000 cells/well, were seeded in 96 well plates and grown in
keratinocyte-SFM/BPE-rEGF medium to confluence as previous-
ly described. Keratinocyte-SFM/BPE-rEGF medium alone, or
keratinocyte-SFM supplemented with 20% serum, was added,
followed by peptide addition to 60 mM. After incubation over
night, 20 ml of the MTT solution was added to each well and the
plates incubated for 1 h in CO2 at 37uC. The MTT- containing
medium was then removed by aspiration. In the assay, MTT is
modified into a dye, blue formazan, by enzymes associated to
metabolic activity. The blue formazan product generated was
dissolved by the addition of 100 ml of 100% DMSO per well. The
plates were then gently swirled for 10 min at room temperature to
dissolve the precipitate. The absorbance was monitored at
550 nm, and results given represent mean values from triplicate
measurements.
Lactate dehydrogenase (LDH) assay
The LDH assay was utilized in order to analyse cell permeation
of keratinocytes. HaCaT keratinocytes were grown in 96 well
plates (3000 cells/well) in serum-free keratinocyte medium (SFM),
Table 2. MIC values for the peptide RRP9W4N against various pathogens, including multiresistant ‘‘superbugs’’.
Bacterial Strain Cation-adjusted Mueller-Hinton broth
RRP9W4N mg/l RRP9W4N mM
Staphylococcus aureus ATCC 29213 – antibiotic-susceptible type strain 16 8.29
Staphylococcus aureus ATCC 43300 – methicillin-resistant type strain 16 8.29
Staphylococcus aureus – methicillin-resistant clinical isolate 32 16.57
Staphylococcus aureus - multi-drug-resistant clinical isolate 32 16.57
Staphylococcus aureus - teicoplanin-intermediate clinical isolate 32 16.57
MU50 Staphylococcus aureus (MRSA) – VISA type strain 32 16.57
EMRSA3 Staphylococcus aureus (MRSA) – SSCmec type 1 16 8.29
EMRSA16 Staphylococcus aureus (MRSA) – SSCmec type 2 32 16.57
EMRSA1 Staphylococcus aureus (MRSA) – SSCmec type 3 32 16.57
EMRSA15 Staphylococcus aureus (MRSA) – SSCmec type 4 16 8.29
HT2001254 Staphylococcus aureus (MRSA) – PVL positive 32 16.57
Staphylococcus epidermidis – antibiotic susceptible clinical isolate 8 4.14
Staphylococcus epidermidis– methicillin-resistant clinical isolate 8 4.14
Staphylococcus haemolyticus – antibiotic susceptible clinical isolate 8 4.14
Staphylococcus saprophyticus – antibiotic susceptible clinical isolate 64 33.14
Group C Streptococcus – antibiotic-susceptible clinical isolate 8 4.14
Group G Streptococcus – antibiotic-susceptible clinical isolate 32 16.57
Group G Streptococcus – macrolide-resistant clinical isolate 16 8.29
Group C Streptococcus – macrolide-resistant clinical isolate 8 4.14
Streptococcus pyogenes – antibiotic-susceptible clinical isolate 32 16.57
Streptococcus pyogenes – Macrolide (M-type) resistance clinical isolate 16 8.29
Streptococcus pyogenes – Macrolide (MLS) resistant clinical isolate 16 8.29
Streptococcus pyogenes – ATCC 19615 16 8.29
Escherichia coli ATCC 25922 - antibiotic-susceptible type strain 16 8.29
Escherichia coli ATCC 35218 - b-lactamase positive type strain 16 8.29
Escherichia coli - multi-drug resistant clinical isolate 16 8.29
Escherichia coli - ESBL - TEM 16 8.29
Escherichia coli - ESBL - CTXM 16 8.29
Escherichia coli - ESBL - SHV 32 16.57
Pseudomonas aeruginosa ATCC 27853 - antibiotic-susceptible type strain 64 33.14
Pseudomonas aeruginosa - multi-drug resistant clinical isolate 128 66.29
Pseudomonas aeruginosa – Liverpool genotype LES 431 128 66.29
MIC assay was carried out by a microtiter broth dilution method as previously described in the NCSLA guidelines [60] in cation-adjusted Mueller-Hinton broth.
doi:10.1371/journal.pone.0016400.t002
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EGF (BPE-rEGF) (Invitrogen, Eugene, USA) to confluency.
The medium was then removed, and 100 ml of the peptides
investigated (at 60 mM, diluted in SFM/BPE-rEGF or in
keratinocyte-SFM supplemented with 20% human serum) added
in triplicates to different wells of the plate. The LDH-based TOX-
7 kit (Sigma-Aldrich, St. Louis, USA) was used for quantification
of LDH release from the cells. Results given represent mean values
from triplicate measurements, and are given as fractional LDH
release compared to the positive control consisting of 1% Triton
X-100 (yielding 100% LDH release).
Hemolysis assay
For analysis of peptide-induced permeabilization of human
erythroytes, EDTA-, or citrate-blood was drawn from healthy
volunteers [26,51], centrifuged at 800 g for 10 min, and plasma
and buffy coat were removed. For experiments using EDTA-
blood, [51] erythrocytes were washed three times and resuspended
to 5% in PBS, pH 7.4. For experiments in 50% blood [26], citrate-
blood was diluted (1:1) with PBS. The cells were then incubated
with end-over-end rotation for 1 h at 37uC in the presence of
peptides (60 mM). 2% Triton X-100 (Sigma-Aldrich, St. Louis,
USA) served as positive control. The samples were then
centrifuged at 800 g for 10 min. The absorbance of hemoglobin
release was measured at 540 nm and is expressed as % of
TritonX-100 induced hemolysis. In the experiments with blood
infected by bacteria, citrate-blood was diluted (1:1) with PBS. The
cells were then incubated with end-over-end rotation for 1 h at
37uC in the presence of peptides (60 and 120 mM) and S. aureus
(2610
8 cfu/ml) or P. aeruginosa (2610
8 cfu/ml) bacteria. For
evaluation of hemolysis, samples were then processed as above.
Results given represent mean values from triplicate measurements.
Antibacterial effects ex vivo
For evaluating antibacterial effects of AMPs ex vivo, a pig skin
model was used as previously described [61], but with modifica-
tions. Defatted pig hides were first washed with water and then
70% ethanol. They were then destubbled with disposable razors
and 868 cm pieces were cut, sealed in plastic wrap, and frozen at
220uC. Before use, the skin samples were thawed, and then
washed with ethanol (70%) and water. In order to separate the
inoculation areas, sterilised tubings (polyethylene, 9.6 m, Nal-
geneH VWR 228-0170) were cut into ,10 mm lengths, and glued
onto the skin samples (cyanoacrylate glue, Henkel, Du ¨sseldorf,
Germany). 6 mm punch biopies were then made, and the
epidermal parts removed, leaving a dermal wound. The wounded
area was infected by adding 1610
6 cfu of an overnight culture of
P. aeruginosa 15159 (clinical chronic ulcer isolate) or S. aureus ATCC
29213 in a total volume of 100 ml of human serum diluted in
phosphate buffered saline (50:50). After an incubation time of
2 hours at 37uC, peptides diluted in serum-PBS (1 mM in 100 ml),
or serum-PBS only, were applied and incubated for 4 hours.
Bacterial sampling was performed by washing the reaction
chambers twice with 250 ml of 10 mM phosphate buffer,
pH 7.4, 0.05wt% Triton X-100, supplemented with 0.1% dextran
sulfate, added to block peptide activity during sampling (average
molecular weight 500 kDa, Sigma-Aldrich, St. Louis, USA). To
evaluate the degree of invasive infection, 8 mm skin biopsies were
taken after discarding the excess of fluids in the chambers. The
biopsies were homogenized, and cfu counts determined.
Liposome preparation and leakage assay
A liposome model was used in order to study permeabilization
of model phospholipid membranes. The liposomes investigated
were either zwitterionic (DOPC/cholesterol 60/40 mol/mol) or
Figure 1. Antibacterial and hemolytic activity of peptides. Minimal inhibitory concentrations (MIC) [60] of the indicated peptide sequences
(see Table 1) based on the original sequences GRRPRPRPRP (GRR10) and RRPRPRPRP (RRP9) against various bacterial isolates are shown in the three
leftmost diagrams. For comparison, the peptides omiganan and LL-37 are included as well. For hemolysis (rightmost bar diagram), erythrocytes were
incubated with the peptides at 60 mM, while 2% Triton X-100 served as positive control. The absorbance of hemoglobin release was measured at
540 nm and is expressed as % of Triton X-100 induced hemolysis. An increased tag-length was associated with low MICs but also increased hemolysis.
doi:10.1371/journal.pone.0016400.g001
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Glycero-3-phosphoglycerol, monosodium salt), DOPE (1,2-dio-
leoyl-sn-Glycero-3-phoshoetanolamine), and DOPC (1,2-dioleoyl-
sn-glycero-3-phoshocholine) were all from Avanti Polar Lipids
(Alabaster, USA) and of .99% purity, while cholesterol (of .99%
purity), was from Sigma-Aldrich (St. Louis, USA). The lipid
mixtures were dissolved in chloroform, after which solvent was
removed by evaporation under vacuum overnight. Subsequently,
10 mM Tris buffer, pH 7.4 (with or without 150 mM NaCl), was
added together with 0.1 M carboxyfluorescein (CF) (Sigma, St.
Louis, USA). After hydration, the lipid mixture was subjected to
eight freeze-thaw cycles consisting of freezing in liquid nitrogen
and heating to 60uC. Unilamellar liposomes of about Ø140 nm
were generated by multiple extrusions through polycarbonate
filters (pore size 100 nm) mounted in a LipoFast miniextruder
(Avestin, Ottawa, Canada) at 22uC. Untrapped CF was removed
by two subsequent gel filtrations (Sephadex G-50, GE Healthcare,
Uppsala, Sweden) at 22uC, with Tris buffer (with or without
150 mM NaCl) as eluent. CF release from the liposomes was
determined by monitoring the emitted fluorescence at 520 nm
from a liposome dispersion (10 mM lipid in 10 mM Tris, pH 7.4).
An absolute leakage scale was obtained by disrupting the
liposomes at the end of each experiment through addition of
0.8 mM Triton X-100 (Sigma-Aldrich, St. Louis, USA). A SPEX-
fluorolog 1650 0.22-m double spectrometer (SPEX Industries,
Edison, USA) was used for the liposome leakage assay. Measure-
ments were performed in triplicate at 37uC.
Fluorescence microscopy
For study of membrane permeabilization, the impermeant
probe FITC was used. E. coli ATCC 25922 bacteria were grown to
mid-logarithmic phase in TSB medium, and bacteria were washed
and resuspended in 10 mM Tris, pH 7.4, 0.15 M NaCl, with
10 mM glucose, to yield a suspension of 1610
7 cfu/ml. 100 mlo f
the bacterial suspension was incubated with 30 mM of the
respective peptides for 2 h at 37uC. Microorganisms were then
immobilized on poly (L-lysine)–coated glass slides by incubation
for 45 min at 30uC, followed by addition onto the slides of 200 ml
of FITC (6 mg/ml) in the appropriate buffers and incubated for
30 min at 30uC. The slides were washed and bacteria fixed by
incubation, first on ice for 15 min, then in room temperature for
45 min in 4% paraformaldehyde. The glass slides were subse-
quently mounted on slides using Prolong Gold antifade reagent
mounting medium (Invitrogen, USA). For fluorescence analysis,
bacteria were visualized using a Nikon Eclipse TE300 (Nikon,
Melville, NY) inverted fluorescence microscope equipped with a
Hamamatsu C4742-95 cooled CCD camera (Hamamatsu, Japan)
and a Plan Apochromat 6100 objective (Olympus, Orangeburg,
NY). Differential interference contrast (Nomarski) imaging was
used for visualization of the microbes themselves.
Statistics
Values are reported as means 6 standard deviation of the
means. To determine significance, analysis of variance with
ANOVA (SigmaStat, SPSS Inc., Chicago, USA), followed by post
hoc testing using the Holm-Sidak method, was used as indicated in
the figure legends, where ‘‘n’’ denotes number of independent
experiments. Significance was accepted at p,0.05.
Results
Initial survey of antibacterial and hemolytic effects
A series of W- and F-amino acid tagged peptides, comprising
W/F-stretches of 3-5 amino acid residues were used as tags for the
template sequences GRRPRPRPRP (GRR10) and RRPRPRPRP
(RRP9). Table 1 illustrates the specific sequence and hydropho-
bicity of the various peptides investigated. As shown in Figure 1,
tagging of these template peptides with W- and F-containing
amino acid stretches yielded low MICs, particulary for tags
containing 4-5 W- or F-residues. For all bacteria, increased tag-
length led to increased antimicrobial activities (resulting in lower
MIC values). For the peptides studied, C-terminal amidation did
not result in significant improvement of activity. The non-tagged
peptides showed no hemolysis above that of the negative control
(Figure 1). Tagging with 3-4 W/F amino acid residues yielded a
slight increase of hemolysis, whereas the longer forms tagged with
WWWWW or FFFFF resulted in significantly increased hemolysis.
It is of note that the hemolytic activity of those tagged peptides,
which showed increased permeabilization of erythrocytes in PBS,
was completely abolished in the presence of human citrate-blood
(Figure S1).
Figure 2. Minimum inhibitory concentrations of indicated
peptides against different S. aureus and P. aeruginosa isolates.
Analysis was performed according to NCSLA guidlines in MH-broth. The
numbers indicate the number of bacterial isolates presenting MIC
breakpoints at the specified concentration range. Some peptides, such
as RRP9WWWWW-NH2 showed low MIC values against both S. aureus
and P. aeruginosa.
doi:10.1371/journal.pone.0016400.g002
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increases in hemolysis, thus exhibiting a preferable therapeutic
index, were selected for further MIC analyses using various S.
aureus and P. aeruginosa clinical isolates. It was noted that several of
the tagged peptides showed MIC values in the range 2.5–40 mM
and 10–40 mM for S. aureus and P. aeruginosa, respectively (Figure 2).
The peptide RRP9W4N was particularly active, with MIC values
lower than those observed for omiganan and LL-37.
Peptide toxicity, membrane selectivity, and effects in
plasma
In order to further delineate possible peptide-mediated toxic
effects on epithelial cells, dose-response studies, using peptides
displaying a low MIC paired with low or moderate increases in
hemolysis (Figure 2), were employed using HaCat keratinocytes
(Figure 3). Similarly to the results obtained with erythrocytes,
tagging increased the permeabilization and concomitantly de-
creased viability, as measured by LDH and MTT, respectively. It
is of note however, that some peptides, e.g., RRP9W4N, showed a
relatively low permeabilizing activity at 60 mM, as well as low
toxicity as demonstrated by the MTT assay. The permeabilizing
activity was concentration dependent, with results for the forms
with 3-4 W/F residues being comparable to those obtained for
omiganan, and in many cases, significantly lower that that of LL-
37 (Figure 3). Hence, considering the obtained MIC values of 2.5–
40 mM, the results indicate that the tagged AMPs display
considerable selectivity for bacterial membranes.
As can be seen in Figure 4A, and using E. coli as model system,
the selected W-tagged peptides induced a significant permeabiliza-
tion of the bacteria when compared with the template sequences.
Correspondingly, the tagged peptides were much more potent
than the corresponding non-tagged ones in causing membrane
rupture of, and leakage from, anionic and bacteria-mimicking
DOPE/DOPG liposomes. In contrast, leakage induction was quite
limited for DOPC/cholesterol liposomes (mimicking eukaryotic
cell membranes) (Figure 4B). Notably, a significantly less selective
liposome leakage induction was observed for omiganan and LL-
37. Selected peptides with low MICs and a relatively high
therapeutic index were further analyzed for antimicrobial activities
in the presence of human plasma. As seen in Figure 5, the tagged
peptides retained antimicrobial activity at 30–60 mM against both
S. aureus and P. aeruginosa.
Protease effects on peptides
We next evaluated the protease stability of the tagged AMPs. As
seen in Figure 6A, GRR10WWWW-NH2 and RRP9WWWW-
NH2 were largely unaffected by the proteolytic actions of human
neutrophil elastase, as well as the bacterial P. aeruginosa elastase and
the two S. aureus enzymes V8 metalloproteinase and aureolysin. Of
note is that the F-tagged forms were degraded by P. aeruginosa
elastase and staphylococcal aureolysin. In contrast, but in
agreement with previous findings, LL-37 was extensively degraded
by all these enzymes. The high stability of the W-tagged peptides is
illustrated by Figure 6B, demonstrating maintained stability of the
Figure 3. Effect of peptides on mammalian cells. Left panel: Cell permeabilizing effects of the indicated peptides on HaCaT cells, were
determined measured by the LDH-based TOX-7 kit. Right panel: The MTT-assay was used to measure viability of HaCaT keratinocytes in the presence
of the indicated peptides. The template peptides GRR10 and GRR10-NH2 did not induce any LDH release, nor did they affect viability of the cells (not
shown). 1% Triton X-100 (yielding 100% LDH release) (+) and buffer (-) are presented as controls. Overall, a high peptide-mediated LDH-release,
particularly at 30-60 mM, was associated with decreased cell viability.
doi:10.1371/journal.pone.0016400.g003
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PLoS ONE | www.plosone.org 7 January 2011 | Volume 6 | Issue 1 | e16400Figure 4. Peptide-mediated permeabilization of bacteria and liposomes. (A) Effects of the indicated peptides on E. coli. E. coli 25922 was
incubated with the indicated peptides (30 mM) after which permeabilization was assessed using the impermeant probe FITC. The upper images in
each row are Nomarski Differential Interference Contrast images, while the lower show FITC fluorescence of bacteria. Hydrophobic tagging increases
peptide-mediated permeabilization of bacteria at physiological salt strength. (B) Effects of peptides on liposomes in the presence and absence of 0.15
M NaCl (salt). The membrane permeabilizing effect, and resulting release of carboxyfluorescein from liposomes, was recorded by fluorescence
spectroscopy. Left and right panel shows anionic DOPE/DOPG (75/25 mol/mol) and zwitterionic DOPC/cholesterol liposomes, respectively. The
tagged peptides RRP9W4N and GRR10W4N show a pronounced preferential action on anionic DOPE/DOPG-containing liposomes (mean values are
presented, n=3).
doi:10.1371/journal.pone.0016400.g004
Figure 5. Activities of selected W- and F-tagged peptides at physiological conditions. In viable count assays, S. aureus ATCC 29213 and P.
aeruginosa ATCC 27853 were subjected to the indicated peptides in 10 mM Tris pH 7.4 containing 0.15 M NaCl and 20% human citrate-plasma.
Identical buffers without peptide were used as controls. The results with the template peptides GRR10-OH and GRR10-NH2 were similar to the
controls (not shown).
doi:10.1371/journal.pone.0016400.g005
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elastase. This in contrast to omiganan, which was degraded during
extended digestion.
Activities of peptides in infected blood and skin wound
models
The stability of the W-tagged peptides, notably RRP9WWWW-
NH2 against a range of proteases, combined with its potent
bactericidal effects, could make this peptide a potential therapeutic
candidate. The antimicrobial peptide RRP9WWWW-NH2 was
therefore added to human blood infected by S. aureus or P.
aeruginosa, and both hemolysis and antibacterial activity was
recorded (in the same sample) to further investigate selectivity in
a relevant biological context. It was observed that the peptide
displayed a striking selectivity, demonstrating almost complete
eradication of bacteria added to the blood, with no accompanying
hemolysis, at a peptide dose of 120 mM. In contrast, killing of P.
aeruginosa and S. aureus by the peptides LL-37 and omiganan was
largely inhibited in this environment, although LL-37 retained
activity against P. aeruginosa at the highest dose. However, at this
level, LL-37 also displayed a significant concomitant hemolysis
(Figure 7). Furthermore, in order to study a potential topical
antimicrobial effect of RRP9WWWW-NH2, a previously estab-
lished ex vivo skin wound infection model was utilized in order to
test the efficiency of this tagged peptide. As seen in Figure 8,
RRP9WWWW-NH2 potently reduced the level of bacteria
particularly at the skin and wound surface. It is of note that
RRP9WWWW-NH2 also reduced deeper bacterial growth,
particularly noted for S. aureus. At 500 mM, RRP9WWWW-NH2
appeared to significantly reduce P. aeruginosa to a higher extent
than omiganan. As expected, the non-tagged template RRP9N
was inactive in all cases. Finally, as presented in Table 2, the
peptide RRP9WWWW-NH2 showed efficiency against various
multiresistant bacterial isolates, including staphylococcal isolates
such as MRSA, macrolide resistant Group A streptococci, E. coli
ESBL, as well as multi-drug resistant P. aeruginosa.
Figure 6. Protease sensitivity of peptides. (A) The indicated W- and F-tagged peptides were incubated with (+) or without (-) human leukocyte
elastase (HLE), the S. aureus enzymes aureolysin (Aur), V8 proteinase (V8), or P. aeruginosa elaslatse (PE) for 4 h at 37uC, and analyzed by SDS-PAGE
(16.5% Tris-Tricine gels). (B) As above, peptides were incubated with P. aeruginosa for different times up to 18 h and analyzed by SDS-PAGE. Reduced
or no staining of peptide indicates partial or complete degradation (peptide fragments are poorly detected). Molecular masses (kDa) are indicated.
doi:10.1371/journal.pone.0016400.g006
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Three main findings are presented in this report. First, it shows
the applicability of hydrophobic tagging as a means for enhancing
antimicrobial potency of ultra-short, highly cationic, and hydro-
philic peptide stretches from AMPs, such as the herein described
sequences from PRELP. Second, the results indicate that a precise
‘‘tuning’’ of toxicity and proteolytic stability may be achieved by
changing tag-length or adding W- or F-amino acid tags, the latter
being particularly sensitive to proteolytic inactivation. Third, the
optimized peptide RRP9WWWW-NH2 retained high antimicro-
bial potency at physiological conditions, including effects against
various multi-drug resistant ‘‘superbugs’’, demonstrated high
selectivity against bacteria in human blood, and showed
therapeutic potential in an ex vivo model of skin wound infection
with P. aeruginosa and S. aureus.
Although hydrophobic modifications can be designed in a
number of ways, including point mutations of individual amino
acids or acyl modification, end-tagging by hydrophobic oligoa-
mino acid stretches constitutes an attractive alternative. It allows
the primary AMP sequence, such as the PRELP-derived sequence
reported here, to be retained, while an efficient, but selective,
membrane anchoring is achieved. W-tagging also does not affect
proteolytic stability of the tagged AMPs detrimentally, a factor of
importance for bactericidal potency on S. aureus and P. aeruginosa,
as well as other bacteria secreting AMP-degrading proteases [62].
The present results also indicate that utilization of F tags may be
an efficient means of reducing proteolytic stability of the AMP in a
controlled way, of potential interest in situations where a rather
limited and time-dependent antimicrobial effect is preferred,
leading to inactivation of the administered AMP and generation of
the completely endogenous template sequence in a prodrug
context.
As mentioned above, AMPs may mediate bacterial killing by
both membrane disruptive and non-disruptive ways. Concerning
membrane disruptive effects, some peptides, such as melittin,
alamethicin, magainin 2 and gramicidin A may form transmem-
brane structures [11,63,64,65]. Disordered and highly charged
peptides, including the ones studied here, disrupt membranes by
other mechanisms, involving generation of negative curvature
strain, membrane thinning, or local packing defects associated
with peptide localization within, or close to, the phospholipid
polar headgroup region [11,30,66,67,68,69]. In the latter cases,
membrane defect formation increases with the amount of peptide
bound to the lipid membrane, hence high peptide adsorption at
the membrane promotes AMP potency [30,66,67,68]. Due to
potential lytic properties of AMPs against bacterial as well as
mammalian membranes, one of the challenges in designing new
peptides relies on developing AMPs with high specificity against
bacterial cells, i.e., a high therapeutic index. The finding that
RRP9WWWW-NH2 displayed no lytic activities against mam-
malian cells in blood, while simultaneously effectively killing
bacteria (Figure 7), suggest a quite remarkable dissociation
Figure 7. Simultaneous analysis of peptide-mediated hemolysis and antibacterial activity in human blood infected by bacteria. S.
aureus and P. aeruginosa (2610
8 cfu/ml) were added to 50% citrate blood, followed by addition of peptide at 60 or 120 mM. (A) Hemolysis in human
blood (made 50% in PBS) in presence of the indicated bacteria as well as peptides is presented. Hemolysis was assessed after 1 hour. 1% Triton X-100
(yielding 100% LDH release) (+) and buffer (-) are presented as controls. (B) Using the same material, antibacterial effects (after 1 hour) of the
indicated peptides were determined. The number of cfu is presented.
doi:10.1371/journal.pone.0016400.g007
Highly Selective Antimicrobial Peptides
PLoS ONE | www.plosone.org 10 January 2011 | Volume 6 | Issue 1 | e16400between antimicrobial and antieukaryotic activities. Taken
together, these data, combined with results from the other
analyses on bacteria, erythrocytes, keratinocytes, and liposomes,
clearly indicate that the W-tagged peptide displays a high
selectivity against negatively charged bacterial membranes.
Likely, the underlying mechanism for the latter selectivity
depends on the fact that bulky groups such as W and F require
substantial area expansion for their incorporation in phospholipid
membranes [70], and therefore tag insertion into zwitterionic
eukaryotic membranes containing strongly membrane-condens-
ing cholesterol becomes an energetically costly process, whereas
the driving force to peptide binding is higher, and the energetic
penalty for peptide incorporation in the phospholipid membrane
is lower, for highly negatively charged and cholesterol-void
bacterial membranes.
From a clinical perspective, alternatives to antibiotics and
antiseptics are highly needed. A number of different antimicrobial
strategies may be deployed for the prevention or treatment of
infected wounds. Concerning topical antimicrobials, various
antiseptics have long and commonly been used on wounds to
prevent or treat infection. Several antiseptic categories exist,
including alcohols (ethanol), anilides (triclocarban), biguanides
(chlorhexidine), bisphenols (triclosan), chlorine compounds,
iodine compounds, silver compounds, peroxygens, and quater-
nary ammonium compounds [71]. Various antimicrobial agents
are used for both intact skin and wounds, although concerns are
raised based upon effects on human cells and wound healing,
such as those observed for silver [34,72]. Furthermore, although
the multifaceted effect of silver carries a low risk of resistance,
studies in burn wounds have shown that bacteria, and in
particular P. aeruginosa may become resistant to silver compounds
(such as silver sulfadiazine and silver nitrate) [34]. As mentioned
above, various AMPs may constitute new therapeutic alternatives
for topical use. Attractive features of the tagged AMPs presented
in this study include a broad-spectrum activity against multire-
sistant bacteria and efficiency in ex vivo wound infection models, a
high selectivity and low toxicity, and the possibility of precise
‘‘tuning’’ of both effect and proteolytic stability. Clearly, further
investigations involving in vivo animal models, toxicological
analyses, as well as clinical studies, are mandated in order to
further explore the potential of these AMPs as novel antiinfec-
tives.
Supporting Information
Figure S1 Hemolytic activity of peptides in human
blood. Citrate-blood was diluted (1:1) with PBS. The cells were
then incubated with end-over-end rotation for 1 h at 37uC in the
presence of the indicated peptides (at 60 mM). 2% Triton X-100
(Sigma-Aldrich) served as positive control. The samples were then
centrifuged at 800 g for 10 min. The absorbance of hemoglobin
release was measured at l 540 nm and is in the plot expressed as
% of TritonX-100 induced hemolysis.
(PDF)
Figure 8. Activities of peptides in an ex vivo skin infection model. 6 mm punch biopies were made to pig skin, and the epidermal parts
removed, leaving a dermal wound. The wounded area was infected by P. aeruginosa 15159 (clinical chronic ulcer isolate) or S. aureus ATCC 29213.
After an incubation time of 2 hours at 37uC, the peptides RRP9-NH2, RRP9WWWW-NH2, and omiganan in buffer were applied and incubated for
4 hours (see Material and Methods). Surface-associated bacteria-containing material was collected and CFU determined (surface). To evaluate the
degree of invasive infection, skin biopsies were thereafter made, homogenized, and the number of cfu determined (skin) (mean values are presented,
n=3. Note the logarithmic scale on the y-axis). In contrast to the control peptide, RRP9WWWW-NH2 reduced the level of bacteria, particularly at the
skin and wound surface. (There is a statistically significant difference (P,0.001 two way ANOVA) between the tagged peptide vs. control as well as
the native peptide (RRP9NH2) at the two doses.).
doi:10.1371/journal.pone.0016400.g008
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